Acute decompensated heart failure. What are we missing?
Article Sidebar
Published:
Sep 24, 2019
Keywords:
Acute decompensated heart failure, pulmonary congestion, left ventricular ejection fraction
Main Article Content
Abstract
The treatment of chronic heart failure, particularly when due to systolic dysfunction, is built around therapies that have been shown to reduce long-term mortality and improve symptoms such as: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers and aldosterone antagonists. More recent evidence-based management includes device therapy such as Cardiac Resynchronization Therapy (CRT), Implantable Cardiovertor Defibrillator (ICD) or the Ventricular Assist Device (VAD).
Article Details
How to Cite
1.
Sukhum P P. Acute decompensated heart failure. What are we missing?. BKK Med J [Internet]. 2019 Sep. 24 [cited 2024 Dec. 22];3(1):79. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/217919
Issue
Section
Reviews Article
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: Current state and framework for future research. International Working Group on Acute Heart Failure Syndromes. Circulation 2005;112:3958-68.
2. Gheorghiade M and Pang PS. Acute heart failure syndromes. J Am CollCardiol 2009; 53:557-73.
3. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
4. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committee for Practice Guideline (CPG). The guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
5. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
6. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. Heart Failure Society of America. J Card Fail 2010;16:1-194.
7. Hunt SA, Abraham WT, Casey DE Jr., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1-82.
8. ESCAPE. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-33.
9. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
10. Nieminen MS, Brutsaert D, Dickstein K, et al.EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36.
11. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77.
12. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunitiesto improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):21-30.
13. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1991;90:353-9.
14. Butman SM, Ewy GA, Standen JR, et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993;22:968-74.
15. Wang CS, Fitzgerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure. JAMA 2005;294:1944-56.
16. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
17. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
18. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
19. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial-the SAVE Investigators. N Eng J Med 1992;327:669-77.
20. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection trials. Circulation 2004;110:2618-26.
21. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, cap-topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
22. CIBIS Investigators and Committees. A randomized trial of beta blockade in heart failure: the Cardiac Insufficiency Bisoprolol . Study (CIBIS). Circulation 1994;90:1765-73.
23. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL. Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302.
24. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
25. Binanay C, Califf RM, Hasselblad V, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness. The ESCAPE Trial. JAMA 2005; 294:1625-33.
26. Fonarow GC. Final hemodynamic measurement in 456 advanced HF patients after tailored vasodilator therapy. Circulation 1994;90:I-488.
27. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symtoms of heart failure. Am Heart J 2000;140:840-7.
28. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
29. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. NEJM 1989;320:677-83.
30. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intra-venous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
31. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1990;82:774-80.
32. Goldberg AD, Goldstein S, Nicldas J. Multicenter trial of imazodan m patients with chronic congestive heart failure. Circulation 1990; 82(Suppl II):1-673.
33. Cohn JN, Goldstein SO, Greenberg BH, et al. A dosedependent increase in mortality with vesnarinone among patientswith severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-6.
34. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74:II-38.
35. O’Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138: 78-86.
36. The Xamoterol in Severe Heart Failure Study Group . Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
37. Hamp JR, van Veldhuisen DJ, Kleber FX et al. Randomised study of effect of ibopamine on survival in patientswith advanced severe heart failure. Lancet 1997;349:971-7.
38. Kleiman N S, Califf R M. Results from late -breaking clinical trial sessions at ACCIS 2000 and 2000. J Am Coll Car 2000;36:310-25.
39. Thackray S, Witte K, Clark AL, et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2:209-12.
40. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
41. Chiolero R., Borgeat A., Fisher A. Postoperative arrhythmias and risk factors after open heart surgery. Thorac Cardiovasc Surgeon 1991;39:81-4.
42. Colucci WS. Niseretide for the treatment of decompesated heartfailure. J Card Fail 2001;7:92-100.
43. Hoffman BB, Lefkowitz RJ. The Pharmacologic Basis of Therapeutics, Goodman and Gilman Edi (9th ed), Chapter 10, 1996 (CD-ROM).
44. Aronson D, Horton DP, Burger AJ. The effect of dobutamine on neurohormonal and cytokine profiles in patients with decompensated congestive heart failure. J Card Fail 2001;7(suppl 2):28;Abstract 095.
45. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.
2. Gheorghiade M and Pang PS. Acute heart failure syndromes. J Am CollCardiol 2009; 53:557-73.
3. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
4. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committee for Practice Guideline (CPG). The guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
5. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
6. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. Heart Failure Society of America. J Card Fail 2010;16:1-194.
7. Hunt SA, Abraham WT, Casey DE Jr., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1-82.
8. ESCAPE. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-33.
9. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
10. Nieminen MS, Brutsaert D, Dickstein K, et al.EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36.
11. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77.
12. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunitiesto improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):21-30.
13. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1991;90:353-9.
14. Butman SM, Ewy GA, Standen JR, et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol 1993;22:968-74.
15. Wang CS, Fitzgerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure. JAMA 2005;294:1944-56.
16. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
17. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
18. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
19. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial-the SAVE Investigators. N Eng J Med 1992;327:669-77.
20. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection trials. Circulation 2004;110:2618-26.
21. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, cap-topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
22. CIBIS Investigators and Committees. A randomized trial of beta blockade in heart failure: the Cardiac Insufficiency Bisoprolol . Study (CIBIS). Circulation 1994;90:1765-73.
23. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL. Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302.
24. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
25. Binanay C, Califf RM, Hasselblad V, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness. The ESCAPE Trial. JAMA 2005; 294:1625-33.
26. Fonarow GC. Final hemodynamic measurement in 456 advanced HF patients after tailored vasodilator therapy. Circulation 1994;90:I-488.
27. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symtoms of heart failure. Am Heart J 2000;140:840-7.
28. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
29. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. NEJM 1989;320:677-83.
30. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intra-venous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
31. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1990;82:774-80.
32. Goldberg AD, Goldstein S, Nicldas J. Multicenter trial of imazodan m patients with chronic congestive heart failure. Circulation 1990; 82(Suppl II):1-673.
33. Cohn JN, Goldstein SO, Greenberg BH, et al. A dosedependent increase in mortality with vesnarinone among patientswith severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-6.
34. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74:II-38.
35. O’Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138: 78-86.
36. The Xamoterol in Severe Heart Failure Study Group . Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
37. Hamp JR, van Veldhuisen DJ, Kleber FX et al. Randomised study of effect of ibopamine on survival in patientswith advanced severe heart failure. Lancet 1997;349:971-7.
38. Kleiman N S, Califf R M. Results from late -breaking clinical trial sessions at ACCIS 2000 and 2000. J Am Coll Car 2000;36:310-25.
39. Thackray S, Witte K, Clark AL, et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000;2:209-12.
40. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
41. Chiolero R., Borgeat A., Fisher A. Postoperative arrhythmias and risk factors after open heart surgery. Thorac Cardiovasc Surgeon 1991;39:81-4.
42. Colucci WS. Niseretide for the treatment of decompesated heartfailure. J Card Fail 2001;7:92-100.
43. Hoffman BB, Lefkowitz RJ. The Pharmacologic Basis of Therapeutics, Goodman and Gilman Edi (9th ed), Chapter 10, 1996 (CD-ROM).
44. Aronson D, Horton DP, Burger AJ. The effect of dobutamine on neurohormonal and cytokine profiles in patients with decompensated congestive heart failure. J Card Fail 2001;7(suppl 2):28;Abstract 095.
45. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.